Paracetamol suspension after a heatwave: release or reject?
A district drug inspector samples a batch of paracetamol oral suspension (120 mg/5 mL, 60 mL bottle) from a retail pharmacy. The label says 'Store below 25°C; protect from light.' The pharmacy's back room reached 38°C for 72 hours during a heatwave because the air conditioner failed. The inspector notices fine needle-like crystals at the bottom of one bottle. The assay later reports 91.5% of the labelled paracetamol content, and the pH is 5.9 (specification 5.0–6.5). The manufacturer's stability data supports 24 months at 25°C/60% relative humidity, with no data for short-term excursions. The pharmacy argues that because the pH is within specification, the product is still acceptable and should be returned to the shelf. The inspector must decide whether to release, quarantine, or recommend recall.
1. Is the batch releasable? Justify your answer using all the data, including the pharmacy's pH argument.
Read the worked answer
No. Release requires every specification to be met. The assay of 91.5% is below the typical 95.0–105.0% limit for paracetamol oral suspension, so it is an out-of-specification result. Visible needle-like crystals are a physical instability, regardless of pH. The pH of 5.9 is within 5.0–6.5, but pH is only one parameter; it does not prove assay, degradant levels, or redispersibility. The 38°C/72-hour excursion invalidates the 25°C/60% RH stability assumption because the manufacturer has no data for that excursion. The pharmacy is selecting one passing test and ignoring two compromised attributes. The batch should be quarantined and not released; if it has already been distributed, a recall assessment is needed. The inspector should also check other bottles from the same batch and the pharmacy's temperature logs.
2. What are the likely causes of the crystals and the assay loss, and what confirmatory tests should be run?
Read the worked answer
Heat accelerates hydrolysis of paracetamol to p-aminophenol and acetic acid, which explains assay loss. The suspension is also a supersaturated sugar solution; high temperature can cause water loss or evaporation, and subsequent cooling can cause sugar or drug crystallization. Confirmatory tests should include HPLC assay and related substances, especially p-aminophenol, microscopy of the crystals, redispersibility or shake tests, particle-size analysis, pH, microbial limits because preservative efficacy may be compromised, and container-closure integrity. If p-aminophenol exceeds its limit, hydrolysis is confirmed. A passing pH does not exclude hydrolysis because the formulation may be buffered. The judgement is that visible crystals plus an out-of-specification assay cannot be rescued by a normal pH.
3. What preventive and regulatory actions should follow?
Read the worked answer
Preventive actions include validated temperature monitoring and alarms in the pharmacy, a written excursion procedure with immediate quarantine, staff training, and storage away from heat sources. The manufacturer should generate short-term excursion stability data and set limits for p-aminophenol and crystallization. Regulatory actions include reporting to the manufacturer and drug inspector, keeping the batch quarantined, and not returning it to sale. If distributed, recall classification should reflect the visible physical defect and assay failure. The broader lesson is that quality cannot be established by one passing test after a known temperature excursion; the batch must be judged against its full specification and stability history.